1 Royal Brisbane and Women's Hospital, Herston, Queensland, Australia ; 2 School of Medicine, University of Queensland, St Lucia, Queensland, Australia ; 3 The Prince Charles Hospital, Chermside, Queensland, Australia.
Transl Lung Cancer Res. 2015 Feb;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01.
In recent years, there has been a major paradigm shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver mutation if one is known or present. Translational research advances now allow such mutations to be inhibited by either receptor monoclonal antibodies (mAb) or small molecule tyrosine kinase inhibitors (TKI). Whilst empirical chemotherapy with a platinum-doublet remains the gold standard for advanced NSCLC without a known driver mutation, targeted therapy is pushing the boundary to significantly improve patient outcomes and quality of life. In this review, we will examine the major subtypes of oncogenic drivers behind NSCLC as well as the development of targeted agents available to treat them both now and in the foreseeable future.
近年来，非小细胞肺癌（NSCLC）的治疗模式发生了重大转变。如果已知或存在驱动突变，现在应进一步根据组织学和驱动突变对 NSCLC 进行分类。转化研究的进展使得这些突变可以被受体单克隆抗体（mAb）或小分子酪氨酸激酶抑制剂（TKI）抑制。虽然对于没有已知驱动突变的晚期 NSCLC，经验性含铂双药化疗仍然是金标准，但靶向治疗正在推动显著改善患者预后和生活质量的边界。在这篇综述中，我们将研究 NSCLC 背后的主要致癌驱动子亚型，以及目前和可预见的未来用于治疗它们的靶向药物的发展。
